ArticleThe world journal of men's health2026
Inhibition of Ferroptosis in Prostatitis Model by Low Intensity Extracorporeal Shock Wave Therapy through the Integrin-β1/NRF2 Axis.
Article in The world journal of men's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeAlthough low-intensity extracorporeal shock wave therapy (Li-ESWT) is used clinically for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), its mechanisms remain inadequately understood. This study aimed to explore Li-ESWT-mediated mechanotransduction signaling and its association with ferroptosis in CP/CPPS models. MATERIALS AND
methodsExperimental autoimmune prostatitis (EAP) was induced by intradermal prostate antigen immunization. Rats received Li-ESWT, with additional groups treated with the ferroptosis inducer RAS-selective lethal 3 (RSL3) or iron chelator deferoxamine (DFO). The rats were analyzed histologically and biochemically to assess immune responses, fibrosis, oxidative stress, ferroptosis markers, and related signaling.
resultsEAP rats recapitulated key pathological features of CP/CPPS, which were alleviated by Li-ESWT. Specifically, Li-ESWT reduced the inflammatory response by inhibiting CD3⁺ T cells and CD68⁺ macrophages infiltration, suppressed fibrosis by preventing epithelial-mesenchymal transition and smooth muscle hyperplasia, and attenuated hyperalgesia by inhibiting mast cell degranulation. RSL3 exacerbated these pathological changes, whereas DFO attenuated them. Li-ESWT also suppressed oxidative stress and ferroptosis, as indicated by reduced reactive oxygen species and ferrous iron accumulation, lipid peroxidation, and ferroptosis-driving factors (ACSL4, LPCAT3, ALOX15, COX-2) levels. Li-ESWT also upregulated the Integrin-β1 and NRF2-xCT/GPX4 expression.
conclusionsLi-ESWT ameliorates inflammation, fibrosis, hyperalgesia in the CP/CPPS model, likely through ferroptosis mitigation
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.